Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.
TLDR
In this article, inflammatory cytokines are considered to be responsible for a highly deleterious pathophysiologic process: the phenotypic transformation of polycythemia vera (PV) or essential thrombocythemia (ET), and the equivalent emergence of primary myelofibrosis (PMF).Abstract:
Myeloid neoplasms, including acute myeloid leukemia (AML), myeloproliferative neoplasms (MPNs), and myelodysplastic syndromes (MDS), feature clonal dominance and remodeling of the bone marrow niche in a manner that promotes malignant over non-malignant hematopoiesis. This take-over of hematopoiesis by the malignant clone is hypothesized to include hyperactivation of inflammatory signaling and overproduction of inflammatory cytokines. In the Ph-negative MPNs, inflammatory cytokines are considered to be responsible for a highly deleterious pathophysiologic process: the phenotypic transformation of polycythemia vera (PV) or essential thrombocythemia (ET) to secondary myelofibrosis (MF), and the equivalent emergence of primary myelofibrosis (PMF). Bone marrow fibrosis itself is thought to be mediated heavily by the cytokine TGF-β, and possibly other cytokines produced as a result of hyperactivated JAK2 kinase in the malignant clone. MF also features extramedullary hematopoiesis and progression to bone marrow failure, both of which may be mediated in part by responses to cytokines. In MF, elevated levels of individual cytokines in plasma are adverse prognostic indicators: elevated IL-8/CXCL8, in particular, predicts risk of transformation of MF to secondary AML (sAML). Tumor necrosis factor (TNF, also known as TNFα), may underlie malignant clonal dominance, based on results from mouse models. Human PV and ET, as well as MF, harbor overproduction of multiple cytokines, above what is observed in normal aging, which can lead to cellular signaling abnormalities separate from those directly mediated by hyperactivated JAK2 or MPL kinases. Evidence that NFκB pathway signaling is frequently hyperactivated in a pan-hematopoietic pattern in MPNs, including in cells outside the malignant clone, emphasizes that MPNs are pan-hematopoietic diseases, which remodel the bone marrow milieu to favor persistence of the malignancy. Clinical evidence that JAK2 inhibition by ruxolitinib in MF neither reliably reduces malignant clonal burden nor eliminates cytokine elevations, suggests targeting cytokine mediated signaling as a therapeutic strategy, which is being pursued in new clinical trials. Greater knowledge of inflammatory pathophysiology in MPNs can therefore contribute to the development of more effective therapy.read more
Citations
More filters
Journal ArticleDOI
Putative Role of Neutrophil Extracellular Trap Formation in Chronic Myeloproliferative Neoplasms
TL;DR: In this paper , the potential pathophysiological relevance of neutrophil extracellular trap (NET) formation in MPNs is discussed, with the intention of contributing to a better understanding of how neutrophils and neutrophin clonality can orchestrate the evolution of a pathological microenvironment in MPN.
Journal ArticleDOI
How I manage anemia related to myelofibrosis and its treatment regimens
TL;DR: In this article , the authors provide treatment and patient management approaches for both types of anemia presentations and provide recommendations for the treatment of myelofibrosis patients in the presence of the anemia.
Journal ArticleDOI
Primary Arterial Hypertension and Drug-Induced Hypertension in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review
Mihnea-Alexandru Găman,Vincent Kipkorir,Bahadar S Srichawla,Arkadeep Dhali,Amelia Maria Găman,Camelia Cristina Diaconu +5 more
TL;DR: In this paper , the authors conducted a systematic review of the available literature and shed light on the occurrence of primary arterial hypertension (HTN) in myeloproliferative neoplasms (MPNs) and its association with thrombosis, as well as the drugs used in MPN management that could increase blood pressure.
Posted ContentDOI
Multiomic Profiling Reveals Metabolic Alterations Mediating Aberrant Platelet Activity and Inflammation in Myeloproliferative Neoplasms
Fan He,Angelo BA Laranjeira,Tim Kong,Alice M. Liu,Katrina J. Ashworth,Nina M. Lasky,Daniel A.C. Fisher,Maggie J. Cox,Mary C. Fulbright,Lilian Antunes Heck,Layow Yu,Stephen M. Sykes,Angelo D'Alessandro,Jorge Di Paola,Stephen T. Oh +14 more
TL;DR: In this article , the authors found elevated P-selectin exposure and platelet-leukocyte aggregates indicating activation of platelets from essential thrombocythemia (ET) patients.
Journal ArticleDOI
Age‐related macular degeneration and myeloproliferative neoplasms – A common pathway
TL;DR: Aldersrelateret makuladegeneration (AMD) as mentioned in this paper is one of the most widely used makula-generative methods for cancer treatment in the world.
References
More filters
Journal ArticleDOI
Cancer-related inflammation.
TL;DR: The molecular pathways of this cancer-related inflammation are now being unravelled, resulting in the identification of new target molecules that could lead to improved diagnosis and treatment.
Journal ArticleDOI
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl,Heinz Gisslinger,Ashot S. Harutyunyan,Harini Nivarthi,Elisa Rumi,Jelena D. Milosevic,Nicole C.C. Them,Tiina Berg,Bettina Gisslinger,Daniela Pietra,Doris Chen,Gregory I. Vladimer,Klaudia Bagienski,Chiara Milanesi,Ilaria Carola Casetti,Emanuela Sant'Antonio,Virginia Valeria Ferretti,Chiara Elena,Fiorella Schischlik,Ciara Cleary,Melanie Six,Martin Schalling,Andreas Schönegger,Christoph Bock,Luca Malcovati,Cristiana Pascutto,Giulio Superti-Furga,Mario Cazzola,Robert Kralovics +28 more
TL;DR: Most patients with essential thrombocythemia or primary myelofibrosis that was not associated with a JAK2 or MPL alteration carried a somatic mutation in CALR, and patients with mutated CALR had a lower risk ofThrombosis and longer overall survival than patients with mutations in J AK2.
Journal ArticleDOI
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek,Ruben A. Mesa,Jason Gotlib,Richard S. Levy,Vikas Gupta,John F. DiPersio,John Catalano,Michael W. Deininger,Michael W. Deininger,Carole B. Miller,Richard T. Silver,Moshe Talpaz,Elliott F. Winton,Jimmie H. Harvey,Murat O. Arcasoy,Elizabeth O. Hexner,Roger M. Lyons,Ronald Paquette,Azra Raza,Kris Vaddi,Susan Erickson-Viitanen,Iphigenia L. Koumenis,William Sun,Victor Sandor,Hagop M. Kantarjian +24 more
TL;DR: Ruxolitinib provided significant clinical benefits in patients with myel ofibrosis by reducing spleen size, ameliorating debilitating myelofibrosis-related symptoms, and improving overall survival.
Journal ArticleDOI
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Jyoti Nangalia,Charles E. Massie,E J Baxter,Francesca L. Nice,Gunes Gundem,David C. Wedge,Edward Avezov,Juan Li,Karoline Kollmann,David G. Kent,Athar Aziz,Anna L. Godfrey,Jonathon Hinton,Inigo Martincorena,P Van Loo,Amy V. Jones,Paola Guglielmelli,P. S. Tarpey,Heather P. Harding,J.D. Fitzpatrick,C.T. Goudie,Christina A. Ortmann,Stephen J. Loughran,Keiran Raine,David R. Jones,Adam Butler,Jon W. Teague,Sarah O’Meara,Stuart McLaren,M. Bianchi,Yvonne Silber,D. Dimitropoulou,David Bloxham,L. Mudie,Mark Maddison,Bruce W. S. Robinson,Clodagh Keohane,Cathy MacLean,Kate Hill,Kim Orchard,Sudhir Tauro,Ming-Qing Du,Mel Greaves,David G. Bowen,Brian J. P. Huntly,Claire N. Harrison,Nicholas C.P. Cross,David Ron,Alessandro M. Vannucchi,Elli Papaemmanuil,Peter J. Campbell,Anthony R. Green +51 more
TL;DR: Somatic mutations in the endoplasmic reticulum chaperone CALR were found in a majority of patients with myeloproliferative neoplasms with nonmutated JAK2, a finding consistent with its role as an initiating mutation in some patients.
Journal ArticleDOI
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Claire N. Harrison,Jean-Jacques Kiladjian,Haifa Kathrin Al-Ali,Heinz Gisslinger,Roger J. Waltzman,Viktoriya Stalbovskaya,Mari McQuitty,Deborah S. Hunter,Richard S. Levy,Laurent Knoops,Francisco Cervantes,Alessandro M. Vannucchi,Tiziano Barbui,Giovanni Barosi +13 more
TL;DR: Continuous ruxolitinib therapy, as compared with the best available therapy, was associated with marked and durable reductions in splenomegaly and disease-related symptoms, improvements in role functioning and quality of life, and modest toxic effects.